



**GUIDELINES FOR THE CANCELLATION/ SUSPENSION OF
MARKETING AUTHORISATION FOR MEDICAL PRODUCTS**

AUGUST, 2022

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.: 0	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

FOREWORD

Rwanda Food and Drugs Authority (Rwanda FDA) is a regulatory body established by the Law N° 003/2018 of 09/02/2018 determining its mission, organization and functioning. One of its functions is to regulate matters related to quality, safety and efficacy of medicinal products, medical devices and IVDs in order to protect public health by increasing their access and availability.

Considering the provisions of the Regulations No. CBD/TRG/010 governing the registration of medicinal products and Regulation No. CBD/TRG/012 governing registration of medical devices including IVDs. Rwanda FDA issues the guidelines for the cancellation/suspension of marketing authorization for medical products.

It is in this regard, that the Authority has developed guidelines No: DFAR/HMDAR/GDL/016 for the cancellation/suspension of marketing authorization for medical products.

Dr. Emile BIENVENU
Director General

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

GUIDELINES DEVELOPMENT HISTORY

DRAFT ZERO	12/08/2022
ADOPTION BY RWANDA FDA	16/08/2022
STAKEHOLDERS CONSULTATION	
ADOPTION OF STAKEHOLDERS' COMMENTS	
DATE FOR COMING INTO EFFECT	

DOCUMENT REVISION HISTORY

Date of revision	Revision number	Changes made and/or reasons for revision
16/08/2022	0	First issue

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

TABLE OF CONTENTS

FOREWORD	2
GUIDELINES DEVELOPMENT HISTORY	3
DOCUMENT REVISION HISTORY	3
TABLE OF CONTENTS	4
ACCRONYMES AND ABBREVIATIONS	5
GLOSSARY/ DEFINITIONS	6
INTRODUCTION	7
SCOPE	7
1. SUSPENSION OF A MARKETING AUTHORIZATION BY THE AUTHORITY	8
2. CANCELLATION OF A MARKETING AUTHORIZATION BY THE AUTHORITY	8
3. SUSPENSION OR CANCELLATION WITHOUT NOTICE	9
4. CANCELLATION/WITHDRAW OF AN APPLICATION	9
5. CANCELLATION OF A MARKETING AUTHORIZATION BY AN APPLICANT	9
ENDORSEMENT OF THE GUIDELINES	10

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

ACCRONYMES AND ABBREVIATIONS

MA: Marketing authorization
IVDs: In vitro diagnostics
CBD: Chair of Board of Directors
TRG: Technical Regulations

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

GLOSSARY/ DEFINITIONS

In this guideline, unless the context otherwise states: -

“Applicant” means a person who applies for registration of a medicinal product to Rwanda FDA, who must be the owner of the product. He may be a manufacturer or a person to whose order and specifications, the product is manufactured. After the product is registered, the applicant shall be the “Marketing Authorisation Holder”.

“Authority” means the Rwanda Food and Drugs Authority or its acronym “Rwanda FDA”, established under the article 2 of the Law No. 003/2018 of 09/02/2018.

“Local technical representative” means any applicant who is not resident in Rwanda shall appoint a local technical representative who must be a company incorporated in Rwanda and authorized by Rwanda FDA to deal in medicinal products and must hold a wholesale operating license. The appointment shall be notified to the Authority by submitting a letter of appointment supported by original copy of power of attorney duly notarised in country of origin,

“Marketing Authorisation” means an approval from the authority necessary to market and sell a product in Rwanda. This is a legal document that establishes the detailed composition and formulation of the product and the pharmacopoeia or other recognized specifications of its ingredients and of the final product itself, and includes details of packaging, labelling and shelf-life.

“Medical product” means medical devices, diagnostics, and pharmaceutical products including any substance capable of preventing, treating human or animal diseases and any other substance intended for administration to a human being or an animal to in order to diagnose diseases, restore, correct or carry out modification of organic or mental functions. It also means products used in disinfecting premises in which food and drugs are manufactured, prepared, or stored, cleaning hospitals, equipment, and farm houses;

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

INTRODUCTION

In pursuance of the Law N° 003/2018 of 09/02/2018 establishing Rwanda Food and Drugs Authority and determining its mission, organization and functioning, especially in article 9;

Considering the provisions of the Regulations No. CBD/TRG/010 governing the registration of medicinal products especially in its articles 24,25,26,27 and 29 concerning cancellation/suspension of marketing authorisation and Regulation No. CBD/TRG/012 governing registration of medical devices including IVDs in its articles 24,25,26,27 and 28 concerning cancellation/suspension of marketing authorisation of medical devices including IVDs;

The Authority has developed these guidelines to provide guidance on cancellation/suspension of marketing authorization for medical products.

SCOPE

These guidelines are hereby made to provide guidance on the cancellation or suspension of the Marketing Authorization of human/veterinary medicinal products, vaccines and biological products for human and animal use, herbal medicinal products, disinfectants and antiseptics, medical devices and IVDs.

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

1. SUSPENSION OF A MARKETING AUTHORIZATION BY THE AUTHORITY

The Authority may suspend a registered medical product if it is satisfied that:

- a) A registered medical product has been advertised in a manner which is false or misleading or does not comply with the provisions of the Laws and Regulations currently enforced by the Authority;
- b) The marketing authorization holder has contravened the Laws and Regulations currently enforced by the Authority;
- c) The marketing authorisation holder made a false or misleading statement or misrepresentation in the application;
- d) The marketing authorisation holder has failed to comply with the terms and conditions of the registration as provided in certificate of registration;
- e) The premises in which the product or part thereof is manufactured, packaged or stored by or on behalf of the holder of the certificate of registration is unsuitable for the manufacturing, packaging or storing of the product.
- f) The marketing authorisation holder has failed to pay the prescribed retention fees within the prescribed time;
- g) The marketing authorisation holder has failed to submit periodic post-marketing surveillance reports;
- h) The marketing authorisation holder, intentionally and without justifiable reasons has failed to submit reports on adverse effects; and
- i) Renewal of registration has been defaulted beyond the specified grace period.

Any suspension shall be effected upon a written notice thereof. The notice for suspension of registered medical product shall:

- a) Set out the reason for the proposed suspension, any corrective action required to be taken and the time within which it must be taken;
- b) Require the marketing authorisation holder to show reasons as to why the suspension should not be effected.

2. CANCELLATION OF A MARKETING AUTHORIZATION BY THE AUTHORITY

The Authority may cancel the marketing authorization of a registered medical product

if:

- a) it is not in the public interest that the registered medical product should be made or continue to be made available;
- b) the medical product has been banned in Rwanda;
- c) the medical product no longer meets the quality, safety and effectiveness requirements; and
- d) the marketing authorisation has been suspended for a period of more than 12 months.

A written notice of cancellation shall then be issued to the marketing authorisation holder, stating the reasons for cancellation.

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

3. SUSPENSION OR CANCELLATION WITHOUT NOTICE

The Authority may cancel or suspend the registration of a medical product without prior notice if it is necessary to do so in order to prevent injury to the health or safety of patients, users or other persons.

The marketing authorization holder may apply to the Authority, in writing, requesting that the cancelation or suspension be uplifted.

The Authority may, within thirty (30) days after the date of receiving the application review its decision.

Where the registration of a product is suspended/canceled based on safety or quality issues, the Authority shall withdraw from circulation of that product from the market.

4. CANCELLATION/WITHDRAW OF AN APPLICATION

- a) In the event that the responses to the queries are not submitted within ninety (90) calendar days from the date they were issued, it will be considered that the applicant has withdrawn the application unless the applicant has requested for extension of deadline to Rwanda FDA. The authority will notify the applicant in writing.
- b) The applicant may withdraw an application of medical product willingly at any stage of the registration process. This may be done by submitting a written letter to the Director General of Rwanda FDA.
- c) The Authority shall act on this request and amend its records within 30 working days.

Thereafter, registration of the product may only be considered upon submission of a new application.

5. CANCELLATION OF A MARKETING AUTHORIZATION BY AN APPLICANT

- a) An applicant may cancel the marketing authorization of a product by submitting a letter addressed to the Director General of the Authority giving reason(s) for the cancellation of marketing authorization of the medical products.
- b) The Authority shall act on this request and amend its records within 30 working days.

An applicant may at any time after cancellation of a registration resubmit a new application on the medical product in line with current requirements for registration.

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY

ENDORSEMENT OF THE GUIDELINES

	Author	Checked by		Approved by
Title	Division manager	Head of Department	Quality Assurance Analyst	Director General
Names	Mrs Clarisse IRASABWA	Dr. Védaste HABYARIMANA	Mr. Théogène NDAYAMBAJE	Dr. Emile BIENVENU
Signature				
Date				

Doc. No.: DFAR/HMDAR/GDL/016	Revision Date: DD/MM/YYYY	Review Due Date: DD/MM/YYYY
Revision No.:	Approval date: DD/MM/YYYY	Effective Date: DD/MM/YYYY